Comments
Cadila Healthcare on Friday informed the exchanges that the US Food and Drug Administration inspected its formulations manufacturing facility at Baddi from July 15 to 19. At the end of the inspection, the USFDA has issued no observations in Form 483. The stock of Cadila Healthcare slipped 1.10 per cent at ₹228.45 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.